Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Leerink Swann dropped their FY2017 EPS estimates for Kura Oncology in a research note issued on Tuesday. Leerink Swann analyst J. Chang now forecasts that the company will earn ($1.49) per share for the year, down from their previous estimate of ($1.45). Leerink Swann currently has a “Outperform” rating and a $18.00 target price on the stock. Leerink Swann also issued estimates for Kura Oncology’s Q4 2017 earnings at ($0.32) EPS and FY2018 earnings at ($1.55) EPS.
Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, November 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.01). ILLEGAL ACTIVITY WARNING: “Leerink Swann Brokers Cut Earnings Estimates for Kura Oncology, Inc. (KURA)” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://ledgergazette.com/2017/11/12/leerink-swann-brokers-cut-earnings-estimates-for-kura-oncology-inc-kura.html.
A number of other brokerages also recently issued reports on KURA. Cowen and Company started coverage on shares of Kura Oncology in a research note on Thursday, September 7th. They issued an “outperform” rating for the company. Zacks Investment Research upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a research note on Saturday, September 9th. ValuEngine cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Cann reiterated a “buy” rating on shares of Kura Oncology in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $17.20.
Kura Oncology (NASDAQ KURA) opened at $16.45 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 13.48 and a quick ratio of 10.79. Kura Oncology has a 12-month low of $4.72 and a 12-month high of $16.75.
Institutional investors and hedge funds have recently bought and sold shares of the stock. State of Wisconsin Investment Board purchased a new stake in Kura Oncology in the 2nd quarter worth $102,000. Rhumbline Advisers purchased a new stake in Kura Oncology in the 2nd quarter worth $131,000. Nationwide Fund Advisors purchased a new stake in Kura Oncology in the 1st quarter worth $136,000. New York State Common Retirement Fund purchased a new stake in Kura Oncology in the 2nd quarter worth $142,000. Finally, OxFORD Asset Management LLP purchased a new stake in Kura Oncology in the 2nd quarter worth $217,000. Hedge funds and other institutional investors own 40.56% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.